PTGS2 and non-small cell lung carcinoma: A recent randomized trial compared in r/r metastatic non-small cell lung cancer (NSCLC) (second-to-fifth-line treatments) such as two biomodulatory therapy approaches, nivolumab at the approved dose level versus metronomic low-dose chemotherapy, pioglitazone, COX-2 inhibitors, and clarithromycin.